The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2022.8775/2022 | DOI Listing |
Publication Analysis
Top Keywords
hepatocellular carcinoma
8
perspectives yttrium-90
4
yttrium-90 radioembolization
4
radioembolization therapeutic
4
therapeutic option
4
option hepatocellular
4
carcinoma therapeutic
4
therapeutic management
4
management hepatocellular
4
carcinoma hcc
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!